A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.
Advanced Solid Tumors|Metastatic Solid Tumors
DRUG: Sevacizumab
Maximum Tolerated Dose (MTD), up to 28 days
Cmax, d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57|tmax, d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57|AUC, d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57|t1/2, d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57|Objective Response Rate (ORR), d29, d86|Disease Control Rate (DCR), d29, d86
This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.